Use of a Commercially Available 12-Gene Assay in the Treatment of Early-Stage Colorectal Cancer: Results from a Nationally Representative Survey of U.S. Oncologists
Background: The Oncotype DX Colon Cancer Assay is a 12-gene assay that measures recurrence risk in stage II and III colorectal cancer patients that help oncologists make treatment decisions. Although adjuvant chemotherapy for patients with resected stage III colorectal cancer is routinely recommended, its benefit remains controversial in stage II colorectal cancer patients; thus, the real-world use of Oncotype DX Colon is of great clinical interest. The purpose of this study was to investigate ...
- Download PDF
- Read In HTML
- 31 Views
- 25 Downloads